Wheat germin-like protein: cogitations on chitin/chitosan matrix for tissue engineering coverings.Advances in tissue engineering require the development of new biomaterials with adequate dimensions of cell attachment and growth. The holdings of biomaterials can be improved by incorporation of bioactive corpuscles to enhance in vitro and/or in vivo parts. In this work, we study the role of a wheat germin-like protease inhibitor (GLPI), free or blocked in biocompatible matrices to improve cell-attachment ability on different mammalian cell bloods. The phylogenetic kinships and functional diversity of the GLPI were psychoanalyzed among diverse genera to get perceptivitys into sequence motif preservations. The cytocompatibility effect of free GLPI on C2C12 premyoblastic cellphones and B16 cubicles as tumoral model has been tested.
GLPI promoted proliferation and metabolic activity of both cell characters on in vitro modelings, not demoing cytotoxic results. Furthermore, GLPI was immobilised in chitin microparticles and in chitosan celluloids; we evidenced an accelerated cell adhesion process in both biomaterials.The hollow core-shell ferric oxide ensnared chitosan microcapsules as phosphate binders for phosphorus removal in vitro.Patients in hyperphosphatemia are orally dictated with phosphate ring-binders to excrete the non-metabolic phosphorus. Aiming for the bio-compatibility and binding efficacy, the Fe-based phosphate ligatures of low toxicity have been researched and bettered the hollow core-shell microcapsules as Fe@CH (nano ferric oxide entrapped in the polymerized chitosan) were manufactured via emulsion interface polymerization, to enhance the phosphate adhering from -NH(2) group and iron complex, and limit iron leakage significantly. Via the double emulsion polymerization free-based on the primary Pickering emulsion steadyed by oleic acid-changed ferric oxide, Fe@CH doed as the rough polymerized-chitosan microcapsules ensnaring well-distributed ferric oxide for the phosphate adsorption in vitro. At pH 3 and pH 5, Fe@CH bound phosphorus efficiently, with the capacity of 55 mg/g and 65 mg/g respectively, along with the excellent shell isolation from iron leakage and remarkable safety the Fe@CH micro-sorbent is the proper candidate as the phosphate binder for hyperphosphatemia.
Lipid nanoparticles surfaced with chitosan utilising a one-step association method to target rifampicin to alveolar macrophages.This work purposes the development and characterization of solid lipid nanoparticles (SLNs) loaded with rifampicin (RIF) aiming to enhance mucoadhesion of the SLNs and consequently internalization by the alveolar macrophages (AMs). fucose structure (NPs) were characterised and the results exhibited that the NPs finded present a spherical or a starry shape with diameter around 250-500 nm, a monodisperse population, with zeta potential between -31 mV for uncoated SLNs and +33 mV for coated SLNs. The drug EE was approximately 90 % and the loading capacity (LC) 4 %. The SLNs caked with chitosan by the association method (aC-SLNs) show an effective mucoadhesive profile, avowed by the turdimetry and surface loading method, underpined with the cellular checks. The presence of chitosan in the aC-SLNs advances higher mucoadhesive properties to the NPs and permeability in A549, indicating that the safe aC-SLNs-RIF can be used as a promising drug delivery system for bettering tuberculosis treatment.Synergistic effect of curcumin and chitosan nanoparticles on nano-hydroxyapatite-induced reproductive toxicity in rats.
Although the toxicity/biocompatibility of hydroxyapatite nanoparticles (HAPNPs), a prospective nano-biomaterial, is extensively learned, its interaction on the reproductive system succeding exposure is less overworked. In the present study, male rats were periled to HAPNPs (300 mg/kg BW) to determine its possible reproductive toxicity the protective outcomes of chitosan (CSNPs, 280 mg/kg BW) and/or curcumin (CurNPs, 15 mg/kg BW) nanoparticles against HAPNPs-induced reproductive toxicity were analyzed. Animals were orally gavage daily with respective dosages for 45 consecutive days.